358 related articles for article (PubMed ID: 33747894)
1. Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer.
Gatti-Mays ME; Gameiro SR; Ozawa Y; Knudson KM; Hicks KC; Palena C; Cordes LM; Steinberg SM; Francis D; Karzai F; Lipkowitz S; Donahue RN; Jochems C; Schlom J; Gulley JL
Front Oncol; 2020; 10():581801. PubMed ID: 33747894
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the tumor microenvironment and anti-tumor efficacy of subcutaneous vs systemic delivery of the bifunctional agent bintrafusp alfa.
Ozawa Y; Hicks KC; Minnar CM; Knudson KM; Schlom J; Gameiro SR
Oncoimmunology; 2021 May; 10(1):1915561. PubMed ID: 33996267
[TBL] [Abstract][Full Text] [Related]
3. Preclinical and clinical studies of bintrafusp alfa, a novel bifunctional anti-PD-L1/TGFβRII agent: Current status.
Gameiro SR; Strauss J; Gulley JL; Schlom J
Exp Biol Med (Maywood); 2022 Jul; 247(13):1124-1134. PubMed ID: 35473390
[TBL] [Abstract][Full Text] [Related]
4. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients With Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors.
Barlesi F; Isambert N; Felip E; Cho BC; Lee DH; Peguero J; Jerusalem G; Penel N; Saada-Bouzid E; Garrido P; Helwig C; Locke G; Ojalvo LS; Gulley JL
Oncologist; 2023 Mar; 28(3):258-267. PubMed ID: 36571770
[TBL] [Abstract][Full Text] [Related]
5. Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances.
Lind H; Gameiro SR; Jochems C; Donahue RN; Strauss J; Gulley JL; Palena C; Schlom J
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32079617
[TBL] [Abstract][Full Text] [Related]
6. Radiolabelling and preclinical characterization of
Burvenich IJG; Goh YW; Guo N; Gan HK; Rigopoulos A; Cao D; Liu Z; Ackermann U; Wichmann CW; McDonald AF; Huynh N; O'Keefe GJ; Gong SJ; Scott FE; Li L; Geng W; Zutshi A; Lan Y; Scott AM
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3075-3088. PubMed ID: 33608805
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer.
Yoo C; Oh DY; Choi HJ; Kudo M; Ueno M; Kondo S; Chen LT; Osada M; Helwig C; Dussault I; Ikeda M
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461347
[TBL] [Abstract][Full Text] [Related]
8. The Use of a Humanized NSG-β2m
Morillon YMI; Smalley Rumfield C; Pellom ST; Sabzevari A; Roller NT; Horn LA; Jochems C; Palena C; Greiner JW; Schlom J
Front Oncol; 2020; 10():549. PubMed ID: 32373533
[TBL] [Abstract][Full Text] [Related]
9. Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE).
de Haas SL; Slamon DJ; Martin M; Press MF; Lewis GD; Lambertini C; Prat A; Lopez-Valverde V; Boulet T; Hurvitz SA
Breast Cancer Res; 2023 Jan; 25(1):2. PubMed ID: 36631725
[TBL] [Abstract][Full Text] [Related]
10. Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses.
Lan Y; Yeung TL; Huang H; Wegener AA; Saha S; Toister-Achituv M; Jenkins MH; Chiu LY; Lazorchak A; Tarcic O; Wang H; Qi J; Locke G; Kalimi D; Qin G; Marelli B; Yu H; Gross AW; Derner MG; Soloviev M; Botte M; Sircar A; Ma H; Sood VD; Zhang D; Jiang F; Lo KM
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35858707
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, safety, and biomarker analyses of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with advanced non-small cell lung cancer.
Rajan A; Abdul Sater H; Rahma O; Agajanian R; Lassoued W; Marté JL; Tsai YT; Donahue RN; Lamping E; Bailey S; Weisman A; Walter-Rodriguez B; Ito R; Vugmeyster Y; Sato M; Machl A; Schlom J; Gulley JL
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38485188
[TBL] [Abstract][Full Text] [Related]
12. Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study.
Hamilton EP; Kaklamani V; Falkson C; Vidal GA; Ward PJ; Patre M; Chui SY; Rotmensch J; Gupta K; Molinero L; Li Y; Emens LA
Clin Breast Cancer; 2021 Dec; 21(6):539-551. PubMed ID: 34154926
[TBL] [Abstract][Full Text] [Related]
13. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
[TBL] [Abstract][Full Text] [Related]
14. Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial.
Cho BC; Lee JS; Wu YL; Cicin I; Dols MC; Ahn MJ; Cuppens K; Veillon R; Nadal E; Dias JM; Martin C; Reck M; Garon EB; Felip E; Paz-Ares L; Mornex F; Vokes EE; Adjei AA; Robinson C; Sato M; Vugmeyster Y; Machl A; Audhuy F; Chaudhary S; Barlesi F
J Thorac Oncol; 2023 Dec; 18(12):1731-1742. PubMed ID: 37597750
[TBL] [Abstract][Full Text] [Related]
15. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort.
Cho BC; Daste A; Ravaud A; Salas S; Isambert N; McClay E; Awada A; Borel C; Ojalvo LS; Helwig C; Rolfe PA; Gulley JL; Penel N
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32641320
[TBL] [Abstract][Full Text] [Related]
16. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies.
Strauss J; Gatti-Mays ME; Cho BC; Hill A; Salas S; McClay E; Redman JM; Sater HA; Donahue RN; Jochems C; Lamping E; Burmeister A; Marté JL; Cordes LM; Bilusic M; Karzai F; Ojalvo LS; Jehl G; Rolfe PA; Hinrichs CS; Madan RA; Schlom J; Gulley JL
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33323462
[TBL] [Abstract][Full Text] [Related]
17. Phase I Study of the Bifunctional Fusion Protein Bintrafusp Alfa in Asian Patients with Advanced Solid Tumors, Including a Hepatocellular Carcinoma Safety-Assessment Cohort.
Doi T; Fujiwara Y; Koyama T; Ikeda M; Helwig C; Watanabe M; Vugmeyster Y; Kudo M
Oncologist; 2020 Sep; 25(9):e1292-e1302. PubMed ID: 32324927
[TBL] [Abstract][Full Text] [Related]
18. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial.
Paz-Ares L; Kim TM; Vicente D; Felip E; Lee DH; Lee KH; Lin CC; Flor MJ; Di Nicola M; Alvarez RM; Dussault I; Helwig C; Ojalvo LS; Gulley JL; Cho BC
J Thorac Oncol; 2020 Jul; 15(7):1210-1222. PubMed ID: 32173464
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine.
Smalley Rumfield C; Pellom ST; Morillon Ii YM; Schlom J; Jochems C
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554612
[TBL] [Abstract][Full Text] [Related]
20. Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer.
Kang YK; Bang YJ; Kondo S; Chung HC; Muro K; Dussault I; Helwig C; Osada M; Doi T
Clin Cancer Res; 2020 Jul; 26(13):3202-3210. PubMed ID: 32299818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
